Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Yan, Edwin B ^a   Frugier, Tony ^b   Lim, Chai K ^c   Heng, Benjamin ^c   Sundaram, Gayathri ^d   Tan, May ^e   Rosenfeld, Jeffrey V ^a,f   Walker, David W ^g   Guillemin, Gilles J ^c   Morganti Kossmann, Maria Cristina ^a,h  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d St Vincent's Centre for Applied Medical Research   (Australia)

^e Queen Elizabeth Hospital   (Malaysia)

^f ALFRED HOSPITAL   (Australia)

^g MONASH MEDICAL CENTRE   (Australia)

^h UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Kynurenine pathway; Patients; Quinolinic acid; Traumatic brain injury; Tryptophan metabolism

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 3 HYDROXYANTHRANILIC ACID OXYGENASE; ANTHRANILIC ACID; ENZYME; EXCITOTOXIN; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENASE; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; KYNURENINE AMINO TRANSFERASE II; MESSENGER RNA; QUINOLINIC ACID; QUINOLINIC ACID PHOSPHORIBOSYL TRANSFERASE; TRYPTOPHAN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; NEUROTOXIN;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN TISSUE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DETERIORATION; FEMALE; GENE EXPRESSION; GLASGOW COMA SCALE; GLASGOW OUTCOME SCALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INJURY SEVERITY; MALE; NEUROTOXICITY; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN EXPRESSION; TISSUE INJURY; TRAUMATIC BRAIN INJURY; ADOLESCENT; BLOOD; BRAIN; BRAIN INJURIES; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; BRAIN; BRAIN INJURIES; CASE-CONTROL STUDIES; FEMALE; GLASGOW OUTCOME SCALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MALE; MIDDLE AGED; NEUROTOXINS; PROGNOSIS; QUINOLINIC ACID; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRYPTOPHAN; YOUNG ADULT;

EID: 84938990841     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0328-2     Document Type: Article

References (69)

1. Miller JD. Head injury. J Neurol Neurosurg Psychiatry. 1993;56:440-7.
2. Guillemin GJ. Quinolinic acid: neurotoxicity. FEBS J. 2012;279:1355.
3. McMenamy RH. Binding of indole analogues to human serum albumin. Effects of fatty acids. J Biol Chem. 1965;240:4235-43.
4. Christensen HN, Albritton LM, Kakuda DK, MacLeod CL. Gene-product designations for amino acid transporters. J Exp Biol. 1994;196:51-7.
5. Sarkhosh K, Tredget EE, Li Y, Kilani RT, Uludag H, Ghahary A. Proliferation of peripheral blood mononuclear cells is suppressed by the indoleamine 2,3-dioxygenase expression of interferon-gamma-treated skin cells in a co-culture system. Wound Repair Regen. 2003;11:337-45.
6. Sarkhosh K, Tredget EE, Karami A, Uludag H, Iwashina T, Kilani RT, et al. Immune cell proliferation is suppressed by the interferon-gamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts populated in collagen gel (FPCG). J Cell Biochem. 2003;90:206-17.
7. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103:4619-21.
8. Swanson KA, Zheng Y, Heidler KM, Mizobuchi T, Wilkes DS. CDllc + cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol. 2004;30:311-8.
9. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol. 2005;31:395-404.
10. Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13:465-77.
11. Foster AC, Vezzani A, French ED, Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett. 1984;48:273-8.
12. Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992;115(Pt 5):1249-73.
13. Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol. 1999;375:87-100.
14. Guillemin GJ, Brew BJ. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep. 2002;7:199-206.
15. Ting KK, Brew B, Guillemin G. The involvement of astrocytes and kynurenine pathway in Alzheimer's disease. Neurotox Res. 2007;12:247-62.
16. Guillemin GJ, Williams KR, Smith DG, Smythe GA, Croitoru-Lamoury J, Brew BJ. Quinolinic acid in the pathogenesis of Alzheimer's disease. Adv Exp Med Biol. 2003;527:167-76.
17. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012;279:1356-65.
18. Heyes MP, Brew BJ, Martin A, Price RW, Salazar AM, Sidtis JJ, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol. 1991;29:202-9.
19. Baratte S, Molinari A, Veneroni O, Speciale C, Benatti L, Salvati P. Temporal and spatial changes of quinolinic acid immunoreactivity in the gerbil hippocampus following transient cerebral ischemia. Brain Res Mol Brain Res. 1998;59:50-7.
20. Haberny KA, Pou S, Eccles CU. Potentiation of quinolinate-induced hippocampal lesions by inhibition of NO synthesis. Neurosci Lett. 1992;146:187-90.
21. Kheramin S, Body S, Mobini S, Ho MY, Velazquez-Martinez DN, Bradshaw CM, et al. Effects of quinolinic acid-induced lesions of the orbital prefrontal cortex on inter-temporal choice: a quantitative analysis. Psychopharmacology (Berl). 2002;165:9-17.
22. Yan E, Castillo-Melendez M, Smythe G, Walker D. Quinolinic acid promotes albumin deposition in Purkinje cell, astrocytic activation and lipid peroxidation in fetal brain. Neuroscience. 2005;134:867-75.
23. Stone TW. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance. Prog Neurobiol. 2001;64:185-218.
24. Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol. 1981;72:411-2.
25. Kalonia H, Kumar P, Kumar A, Nehru B. Effect of caffeic acid and rofecoxib and their combination against intrastriatal quinolinic acid induced oxidative damage, mitochondrial and histological alterations in rats. Inflammopharmacology. 2009;17:211-9.
26. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009;16:77-86.
27. Kerr SJ, Armati PJ, Guillemin GJ, Brew BJ. Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS. 1998;12:355-63.
28. Bell MJ, Kochanek PM, Heyes MP, Wisniewski SR, Sinz EH, Clark RS, et al. Quinolinic acid in the cerebrospinal fluid of children after traumatic brain injury. Crit Care Med. 1999;27:493-7.
29. Sinz EH, Kochanek PM, Heyes MP, Wisniewski SR, Bell MJ, Clark RS, et al. Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans. J Cereb Blood Flow Metab. 1998;18:610-5.
30. Costantino G. Inhibitors of quinolinic acid synthesis: new weapons in the study of neuroinflammatory diseases. Future Med Chem. 2014;6:841-3.
31. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998;15:573-85.
32. Darlington LG, Mackay GM, Forrest CM, Stoy N, George C, Stone TW. Altered kynurenine metabolism correlates with infarct volume in stroke. Eur J Neurosci. 2007;26:2211-21.
33. Smythe GA, Braga O, Brew BJ, Grant RS, Guillemin GJ, Kerr SJ, et al. Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry. Anal Biochem. 2002;301:21-6.
34. Frugier T, Conquest A, McLean C, Currie P, Moses D, Goldshmit Y. Expression and activation of EphA4 in the human brain after traumatic injury. J Neuropathol Exp Neurol. 2012;71:242-50.
35. Frugier T, Crombie D, Conquest A, Tjhong F, Taylor C, Kulkarni T, et al. Modulation of LPA receptor expression in the human brain following neurotrauma. Cell Mol Neurobiol. 2011;31:569-77.
36. Frugier T, Morganti-Kossmann C, O'Reilly D, McLean C. In situ detection of inflammatory mediators in post-mortem human brain tissue following traumatic injury. J Neurotrauma. 2010;27:497-507.
37. Nemeth H, Toldi J, Vecsei L. Role of kynurenines in the central and peripheral nervous systems. Curr Neurovasc Res. 2005;2:249-60.
38. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth. 2007;99:4-9.
39. Fallarino F, Grohmann U, Puccetti P. Indoleamine 2,3-dioxygenase: from catalyst to signaling function. Eur J Immunol. 2012;42:1932-7.
40. Salazar C, Hofer T. Multisite protein phosphorylation-from molecular mechanisms to kinetic models. FEBS J. 2009;276:3177-98.
41. Ziebell JM, Morganti-Kossmann MC. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics. 2010;7:22-30.
42. Woodcock T, Morganti-Kossmann MC. The role of markers of inflammation in traumatic brain injury. Front Neurol. 2013;4:18.
43. Yamada A, Akimoto H, Kagawa S, Guillemin GJ, Takikawa O. Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease. J Neurochem. 2009;110:791-800.
44. Yan EB, Satgunaseelan L, Paul E, Bye N, Nguyen P, Agyapomaa D, et al. Post-traumatic hypoxia is associated with prolonged cerebral cytokine production, higher serum biomarker levels, and poor outcome in patients with severe traumatic brain injury. J Neurotrauma. 2014;31:618-29.
45. Wang Y, Lawson MA, Dantzer R, Kelley KW. LPS-induced indoleamine 2,3-dioxygenase is regulated in an interferon-gamma-independent manner by a JNK signaling pathway in primary murine microglia. Brain Behav Immun. 2010;24:201-9.
46. Ploder M, Spittler A, Schroecksnadel K, Neurauter G, Pelinka LE, Roth E, et al. Tryptophan degradation in multiple trauma patients: survivors compared with non-survivors. Clin Sci (Lond). 2009;116:593-8.
47. Pellegrin K, Neurauter G, Wirleitner B, Fleming AW, Peterson VM, Fuchs D. Enhanced enzymatic degradation of tryptophan by indoleamine 2,3-dioxygenase contributes to the tryptophan-deficient state seen after major trauma. Shock. 2005;23:209-15.
48. Pfefferkorn ER. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A. 1984;81:908-12.
49. Han Q, Cai T, Tagle DA, Li J. Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci. 2010;67:353-68.
50. Han Q, Cai T, Tagle DA, Robinson H, Li J. Substrate specificity and structure of human aminoadipate aminotransferase/kynurenine aminotransferase II. Biosci Rep. 2008;28:205-15.
51. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011;145:863-74.
52. Darlington LG, Forrest CM, Mackay GM, Smith RA, Smith AJ, Stoy N, et al. On the Biological Importance of the 3-hydroxyanthranilic Acid: anthranilic acid ratio. Int J Tryptophan Res. 2010;3:51-9.
53. Forrest CM, Mackay GM, Oxford L, Stoy N, Stone TW, Darlington LG. Kynurenine pathway metabolism in patients with osteoporosis after 2 years of drug treatment. Clin Exp Pharmacol Physiol. 2006;33:1078-87.
54. Stoy N, Mackay GM, Forrest CM, Christofides J, Egerton M, Stone TW, et al. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem. 2005;93:611-23.
55. Forrest CM, Mackay GM, Stoy N, Spiden SL, Taylor R, Stone TW, et al. Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington's disease. J Neurochem. 2010;112:112-22.
56. Mackay GM, Forrest CM, Christofides J, Bridel MA, Mitchell S, Cowlard R, et al. Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling. Clin Exp Pharmacol Physiol. 2009;36:425-35.
57. Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, et al. Characterization of the kynurenine pathway in human neurons. J Neurosci. 2007;27:12884-92.
58. Schwarcz R, Whetsell Jr WO, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983;219:316-8.
59. Whetsell Jr WO, Schwarcz R. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. Neurosci Lett. 1989;97:271-5.
60. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 1986;321:168-71.
61. Vandresen-Filho S, Martins WC, Bertoldo DB, Mancini G, De Bem AF, Tasca CI. Cerebral cortex, hippocampus, striatum and cerebellum show differential susceptibility to quinolinic acid-induced oxidative stress. Neurol Sci 2015.
62. Chen Y, Brew BJ, Guillemin GJ. Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis. J Neurochem. 2011;118:816-25.
63. Iwahashi H, Kawamori H, Fukushima K. Quinolinic acid, alpha-picolinic acid, fusaric acid, and 2,6-pyridinedicarboxylic acid enhance the Fenton reaction in phosphate buffer. Chem Biol Interact. 1999;118:201-15.
64. Santamaria A, Galvan-Arzate S, Lisy V, Ali SF, Duhart HM, Osorio-Rico L, et al. Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport. 2001;12:871-4.
65. Santamaria A, Jimenez-Capdeville ME, Camacho A, Rodriguez-Martinez E, Flores A, Galvan-Arzate S. In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum. Neuroreport. 2001;12:2693-6.
66. von Ruecker AA, Han-Jeon BG, Wild M, Bidlingmaier F. Protein kinase C involvement in lipid peroxidation and cell membrane damage induced by oxygen-based radicals in hepatocytes. Biochem Biophys Res Commun. 1989;163:836-42.
67. Goda K, Kishimoto R, Shimizu S, Hamane Y, Ueda M. Quinolinic acid and active oxygens. Possible contribution of active oxygens during cell death in the brain. Adv Exp Med Biol. 1996;398:247-54.
68. Chen Y, Stankovic R, Cullen KM, Meininger V, Garner B, Coggan S, et al. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox Res. 2010;18:132-42.
69. Martin A, Heyes MP, Salazar AM, Kampen DL, Williams J, Law WA, et al. Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals. J Neuropsychiatry Clin Neurosci. 1992;4:270-9.